What is the success rate of Cabometyx (cabozantinib)?
Cabometyx (cabozantinib) is a tyrosine kinase inhibitor used to treat certain patients with advanced renal cell carcinoma, hepatocellular (liver) cancer, or advanced or metastatic differentiated thyroid cancer.
It is a chemotherapy drug that you take until your cancer starts to get worse - disease progression - or you can no longer tolerate the drug because of side effects or adverse reactions.
How successful Cabometyx is can be measured by how long patients take the treatment for, how long they survive for without their cancer getting worse (progression-free survival), how many months they remain alive for while taking the treatment and how many patients respond to the drug.
How effective is Cabometyx?
| Trial | Duration of treatment | Median progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) |
| METEOR - advanced renal cell carcinoma |
Cabometyx: 7.6 months (range 0.3 - 20.5) vs Everolimus (Afinitor): 4.4 months (range 0.21 - 18.9) |
PFS Cabometyx: 7.4 months (95% CI 5.6, 9.1) vs Everolimus: 3.8 months (95% CI 3.7, 5.4) OS Partial responses only Cabometyx: 17% (95% CI 13%, 22%) vs Everolimus: 3% (95% CI 2%, 6%) |
| CABOSUN - advance renal cell carcinoma |
Cabometyx: 6.5 months (range 0.2 - 28.7) vs Sunitinib (Sutent): 3.1 months (range 0.2 - 25.5) |
PFS Cabometyx: 8.6 months (95% CI 6.8, 14.0) vs Everolimus: 5.3 months (95% CI 3.0, 8.2) ORR |
| CHECKMATE-9ER - advanced renal cell carcinoma, first-line treatment | Cabometyx plus nivolumab (Opdivo): 14 months (range 0.2 - 27) |
PFS Cabometyx: 16.6 months (95% CI 12.5, 24.9) vs Sunitinib: 8.3 months (95% CI 7.0, 9.7) OS Complete and partial responses Cabometyx: 55.7% (95% CI 50.1, 61.2) vs Sunitinib: 27.1% (95% CI 22.4, 32.3) |
| CELESTIAL - advanced hepatocellular carcinoma |
Cabometyx: 3.8 months (range 0.1 - 37.3) vs Placeo: 2.0 months (range 0.0 - 27.2) |
PFS Cabometyx: 5.2 months (95% CI 4.0, 5.5) vs Placebo: 1.9 months (95% CI 1.9, 1.9) OS Partial responses only Cabometyx: 4% (95% CI2.3, 6.0) vs Placebo: 0.4% (95% CI 0.0, 2.3) |
| COSMIC-311 - radioiodine-refractory differentiated thyroid cancer previously treated with VEGFR-targeted therapy |
PFS (updated analysis) Cabometyx: 11 months (95% CI 7.4, 13.8) vs Placebo: 1.9 months (95% CI 1.9, 3.7) ORR (updated analysis) |
Related questions
References
- Food and Drug Administration (FDA). Cabometyx. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s012lbl.pdf. [Accessed September 27, 2021].
Read next
How does Cabometyx work?
Cabometyx (cabozantinib) is a tyrosine kinase inhibitor, which works by helping to stop the out-of-control growth that cancer cells display.
Carbometyx works by blocking the signals between cells that promote the growth of new blood vessels and encourage cells to divide and grow. In doing so, it decreases the ability of tumors to spread (metastasize) to other parts of the body and invade surrounding areas. Continue reading
What is the difference between Cabometyx and Cometriq?
Cabometyx and Cometriq are two brand name drugs that both contain the same active ingredient cabozantinib, but they are not interchangeable.
Cabometyx comes in the form of a tablet (20, 40 and 60 mg) and is used to treat advanced renal cell carcinoma (RCC), advanced RCC as a first-line treatment in combination with nivolumab, hepatocellular carcinoma (HCC) in patients who have previously been treated with sorafenib, and ocally advanced or metastatic differentiated thyroid cancer that has progressed following VEGFR-targeted therapy in people who do not respond to or are unable to take radioactive iodine.
Cometriq comes in the form of a capsule (20 and 80 mg) and is used to treat progressive metastatic medullary thyroid cancer. Continue reading
How long does it take for Lenvima to work?
How long it takes Lenvima takes to work depends on your cancer type, how far it has progressed, past treatments, and your current state of health. Many trials just reported on differences in progression-free survival or overall survival at the end of a set time frame, but analysis of various results, such as Kaplan-Meier Curves, reveal Lenvima appears to start working after 2 months, for cancers such as thyroid cancer, renal cell carcinoma, and endometrial carcinoma. Continue reading
Related medical questions
- How long do you take Lenvima?
- How does Nexavar work? Is it a chemo drug?
- How effective is Nexavar? Does it shrink tumors?
- What type of drug is Lenvima? Is it a chemo drug?
- Is Nexavar cost covered by Medicare?
- How does Retevmo work?
- How effective is Lenvima?
- What is the success rate of Keytruda?
- How long does it take for Keytruda to work?
- What is the difference between Opdivo and Keytruda?
- Pembrolizumab vs. nivolumab: How do they compare?
- How are Inlyta and Keytruda used in kidney cancer?
- How much does Afinitor cost per month?
- What is the difference between Mvasi and Avastin?
- How long can you take Afinitor for?
- Does Votrient cure cancer or shrink tumors?
- How effective are Opdivo and Yervoy when taken together?
- Does Sutent shrink tumors?
- How long do you take Sutent before it starts to work?
- How long does Votrient stay in your system?
- Is Sutent considered a chemotherapy drug?
- Is Votrient a chemotherapy treatment?
- Is Votrient immunotherapy?
- Who makes Bavencio and where is it made?
- What type of drug is Bavencio?
Drug information
Related support groups
- Cabometyx (7 questions, 10 members)
- Cabozantinib (5 questions, 6 members)
- Thyroid Cancer (14 questions, 44 members)
- Renal Cell Carcinoma (31 questions, 102 members)
- Hepatocellular Carcinoma (21 questions, 23 members)